STANFORD SCHOOL OF MEDICINE
Stanford University Medical Center

Conference for Innovative Designs of Clinical Trials and Related Topics

June 19-20, 2009

FREIDENRICH AUDITORIUM
LUCILE PACKARD CHILDREN'S HOSPITAL, STANFORD UNIVERSITY
(For registration, please goto: http://hrp.stanford.edu/conferences/IDCT.html
or email: bchung@stanford.edu)

June 19, 2009 (Friday)

09:15	Philip Lavori, Stanford	Opening remarks

Session I (Chair: Richard Olshen)

09:20	Robert Negrin, Stanford	Regulatory T cells from the bench to the clinic
10:00	Sandy Srinivas, Stanford	Challenges in clinical trial designs in prostate cancer
10:40	Tyler Martin, Dynavax	Innovative and accelerated development of an improved therapeutic for cystic fibrosis: Tobramycin inhalation powder
11:20	Philip Lavori, Stanford	Effectiveness Experiments: challenges and new directions

Session II (Chair: Corry Dekker)

01:50	Anne-Marie Duliege, Affymax	Safety assessment during the development of new drugs: new challenges and statistical considerations
02:30	Joseph Heyse, Merck	Application of sequential stopping boundaries in vaccine safety trials
03:10	Bruce Fireman, Kaiser Permanente	Influenza vaccination and mortality: a novel approach to differentiating vaccine effects from bias

Session III (Chair: Philip Lavori)

04:00	Corry Dekker, Stanford	Influenza A/H1N1 (Swine flu)
04:40	Balasubramanian Narasimhan, Stanford	Statistical software for designing Phase I/II cancer studies

June 20, 2009 (Saturday)

Session IV (Chair: Ying Lu)

08:15	Sue-Jane Wang, FDA	How might adaptive design be useful to learn biomarker predictivity versus to test treatment effect potentially predicted by genomic biomarker classifier?
08:55	Ray Zhu, Eisai	Using regret concept in planning of clinical development of new drugs
09:35	Mei-Chiung Shih, Stanford	A strategic approach to designing Phase II cancer studies

Session V (Chair: Mei-Chiung Shih)

10:30	Janet Wittes, Statistics Collaborative	Adaptive designs: Gaming the system
11:10	Gordon Lan, Johnson & Johnson	The use of conditional power and predictive power in clinical trials
11:50	Eric Holmgren, Genentech	Extending a study beyond its "final" analysis

Session VI (Panel Discussion)

1:30-3:00 Emerging issues in the design and analysis of clinical trials
Dan Anbar, DANA Pharmaceutical Consulting
Agnes Hsiung, NHRI, Taiwan
Tze Leung Lai, Stanford

HRP Redwood Building, 259 Campus Drive, Stanford, CA 94305-5405
*t: 650-723-6426 * f: 650-725-6951*